Decoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein Stability

A new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, “Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.” The successful development of the BCL-2 inhibitor venetoclax, currently approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), encouraged the development of inhibitors that target other antiapoptotic proteins, particularly Myeloid Leukemia 1 (MCL-1). MCL-1 is among the top genes amplified in several cancers and is implicated in cancer progression, drug resistance and poor prognosis. It protects cancer cells from apoptosis and decreases their sensitivity to targeted agents or chemotherapeutics. In this new editorial, researchers Shady I. Tantawy, Natalia Timofeeva, Ana Hernandez, Aloke Sarkar and Varsha Gandhi from The University of Texas MD Anderson Cancer Center discussed their recent investigation into the mechanism of MCL-1 inhibitor (MCL-1i)-induced Mcl-1 protein stability. The team explored underlying molecular mechanisms that contribute to MCL-1i-induced MCL-1 protein accumulation and its implications. Their study revealed a complex and multifaceted nature of MCL-1 protein accumulation in B-cell malignancies upon treatment with MCL-1i (AMG-176 and AZD5991). “Collectively, these findings may have important implications for the development of next-generation MCL-1i with improved efficacy and safety profiles.” DOI - https://doi.org/10.18632/oncotarget.28440 Correspondence to - Aloke Sarkar - asarkar@mdanderson.org, and Varsha Gandhi - vgandhi@mdanderson.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28440 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - AMG-176, AZD5991, B-cell leukemia, MCL-1 inhibitor, MCL-1 protein About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957